News

November 9, 2011 – A group of states and vendors focused on eliminating the barriers to sharing electronic health records (EHRs) issued a set of technical specifications to standardize connections between healthcare providers, health information exchanges (HIEs) and other data-sharing partners.

Home November 09, 2011
Home
News

November 9, 2011 – PETNET Solutions Inc., a wholly owned subsidiary of Siemens Medical Solutions USA Inc., has entered into a nationwide commercial agreement with Eli Lilly and Company that grants Siemens PETNET Solutions the right to manufacture and distribute Lilly’s molecular imaging agent, which is currently under review by the U.S. Food and Drug Administration (FDA) for positron emission tomography (PET) imaging.

Home November 09, 2011
Home
News

Medtronic today announced it received CE (Conformité Européenne) mark for the CoreValve System to be delivered using direct aortic access. The Medtronic CoreValve System is now the only transcatheter aortic valve implantation (TAVI) system approved for direct aortic and subclavian implantation.

Home November 08, 2011
Home
News

November 8, 2011 — Biosensors International Group Ltd. announced final results of the AXXESS PLUS trial, which demonstrated the long-term efficacy and safety of the Axxess stent for patients with coronary bifurcation lesions. The device is a self-expanding bifurcation stent that releases Biolimus A9 from an abluminal biodegradable polymer coating.

Home November 08, 2011
Home
News

November 8, 2011 – Abiomed, a provider of heart support technologies, announced results of an economic study at the annual 2011 Transcatheter Cardiovascular Therapeutics (TCT) conference. The economic study demonstrated that Impella significantly reduced major adverse events at an incremental cost per quality-adjusted life year considered to be cost-effective for advanced cardiovascular technologies. Quality of life benefits included an increase in ejection fraction of over 20 percent and an improvement in New York Heart Association (NYHA) Class III and Class IV heart failure of over 50 percent.

Home November 08, 2011
Home
News

November 8, 2011 – Boston Scientific reports clinical endpoint data from its PLATINUM Long Lesion trial, demonstrating excellent outcomes for the Promus Element everolimus-eluting platinum chromium (PtCr) stent system in patients with long coronary lesions. Results were presented today by Paul S. Teirstein, M.D., of the Scripps Clinic in La Jolla, Calif., and co-principal investigator of the trial, at the Cardiovascular Research Foundation's annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in San Francisco.

Home November 08, 2011
Home
News

November 7, 2011 — The American College of Cardiology Foundation (ACCF), American Heart Association (AHA), and Society for Cardiovascular Angiography and Interventions (SCAI) released a revised guideline for the management of patients undergoing percutaneous coronary intervention (PCI).

Home November 07, 2011
Home
News

November 7, 2011 — This year’s annual meeting of the European Association of Echocardiography (EAE), a registered branch of the European Society of Cardiology (ESC), is changing its name to “EUROECHO & other Imaging Modalities.”

Home November 07, 2011
Home
News

November 7, 2011 — The Million Hearts initiative has announced new partners and commitments, including tools to reach cardiology professionals and consumers to prevent heart attacks and strokes. The announcements were made at the first gathering of Million Hearts? private and public organizations, called the Power of Million Hearts Partnerships.

Home November 07, 2011
Home
News

November 7, 2011 – Abbott announced the company's schedule of key data presentations at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, to be held Nov. 7 – 11 in San Francisco. New data will be presented on two of Abbott's key investigational products: the MitraClip system and the Absorb bioresorbable vascular scaffold (BVS). One-year data for the Xience Prime everolimus-eluting coronary stent system, recently approved by the U.S. Food and Drug Administration (FDA), will also be presented. In addition, long-term data will be presented from the SPIRIT III and SPIRIT IV trials comparing Abbott's Xience V everolimus-eluting coronary stent system to the Taxus express paclitaxel-eluting coronary stent system.

Home November 07, 2011
Home
News

November 7, 2011 – Arterial Remodeling Technologies (ART) reported that in vivo data strongly suggest that its second-generation bioresorbable stent promotes positive arterial remodeling in a post-angioplasty porcine model at three months follow-up. In addition, acute safety data are excellent: there have been more than 250 MACE-free consecutive implantations of its bioresorbable stent in its preclinical phase of development.

Home November 07, 2011
Home
News

November 4, 2011 – PhysioSonics announced that it received a $2.5 million grant from the Telemedicine and Advanced Technology Research Center (TATRC). TATRC is an organization within the headquarters of the U.S. Army Medical Research and Materiel Command, located at Fort Detrick, Maryland. With this grant, PhysioSonics will optimize its proprietary cerebral blood-flow monitor to detect vasospasm. Following a successful launch in the civilian healthcare market, the military will test the blood-flow monitor with the goal of deploying it at military facilities that care for soldiers with traumatic brain injuries (TBI).

Home November 04, 2011
Home
News

November 4, 2011—Miracor Medical Systems GmbH announced that data will be reported during next week’s Transcatheter Cardiovascular Therapeutics (TCT) 2011 scientific meeting in San Francisco. The data show that the PICSO (Pressure-controlled Intermittent Coronary Sinus Occlusion) system is safe and feasible during elective percutaneous coronary intervention (PCI) using a femoral vein approach.

Home November 04, 2011
Home
News

November 4, 2011 – W. L. Gore & Associates announced that Royal Sussex County Hospital in Brighton, United Kingdom, is the first medical center in the United Kingdom to enroll a patient in the Gore REDUCE clinical study. The study is a U.S. Food and Drug Administration (FDA)-approved prospective, randomized, multi-center, international trial designed to demonstrate safety and effectiveness of the Gore HELEX septal occluder for patent foramen ovale (PFO) closure in patients with a history of cryptogenic stroke or imaging-confirmed transient ischemic attack (TIA). The unique study includes up to fifty investigational sites in the United States and Europe. This patient enrollment was achieved by the site’s study investigator, David Hildick-Smith, M.D., director of cardiac research unit, Brighton and Sussex University Hospitals.

Home November 04, 2011
Home
News

November 4, 2011 - Cardiology departments have hosted a variety of software solutions in the past to meet varying demands. A new report from KLAS reveals the cardiology IT market is moving toward consolidation. The report, Cardiology 2012: Will the Complete CVIS Please Stand Up?, explains that as a result of the trend toward consolidation, providers are looking for a technology leader to step up and meet their needs.

Home November 04, 2011
Home
Subscribe Now